Pancreatic Cancer Trial, Recruiting NCT06585072 Sponsor: Shanghai Changzheng Hospital Condition: Pancreatic Cancer
Back to Pancreatic Cancer

Pancreatic Cancer Trial, Recruiting

NCT06585072
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who identify as Chinese (male or female)
  • People aged 18 years or older
  • People with pancreatic cancer who are planned to have pancreas surgery at the hospital running this trial
  • People who have agreed to take part in the Pancreatobiliary Surgery Cohort Study and have signed a consent form
  • People who have already had blood (serum) samples and tissue samples collected and stored at the trial hospital

Who may not be able to join:

  • People who have a previously diagnosed history of diabetes or pre-diabetes, or whose pre-surgery blood sugar levels are above certain thresholds (confirm with trial site for specific values)
  • People whose blood test results show positive islet-associated antibodies (these are markers sometimes linked to certain types of diabetes)
  • People who are taking medications or have hormonal/gland-related health conditions that could increase the risk of developing diabetes as a secondary effect
  • Women who are pregnant or currently breastfeeding
  • People who have cognitive (thinking or memory) difficulties, or any other reason that would prevent them from being able to sign a consent form

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: tuo Li, Prof., Shanghai Changzheng Hospital

Phone: 86-13918507887

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Shanghai Changzheng Hospital
Registry
ClinicalTrials.gov
Start date
3 January 2025
Est. completion
1 September 2026

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Number of Participants Who developed glucose metabolic disorders(pre-diabetes and diabetes mellitus)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov